XTL Biopharmaceuticals Ltd.

Tel Aviv Stock Exchange XTLB.TA

XTL Biopharmaceuticals Ltd. Operating Income Margin for the year ending December 31, 2023

XTL Biopharmaceuticals Ltd. Operating Income Margin is NA for the year ending December 31, 2023. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Tel Aviv Stock Exchange: XTLB.TA

XTL Biopharmaceuticals Ltd.

CEO	Mr. Shlomo Spokone Shalev
IPO Date	Aug. 30, 2005
Location	Israel
Headquarters	5 Badner Street
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Key trends

Past 5 years